2025-03-26FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNETDrug Cabometyx (cabozantinib) · VEGFR inhibitorConditionsEndocrineGastrointestinal
2021-09-17FDA approves cabozantinib for differentiated thyroid cancerDrug Cabometyx (cabozantinib) · VEGFR inhibitorConditionEndocrine